SV Health Investors

Imbria Pharmaceuticals, founded in 2018 and headquartered in Boston, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies targeting cardiometabolic disorders. The company focuses on understanding the underlying mechanisms of these diseases, particularly energetic impairment at the cellular level, to inform its therapeutic candidates. Imbria's pipeline aims to improve the lives of patients suffering from conditions such as non-obstructive hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction by restoring or enhancing cellular energy production.

Founded in 2018, Perfuze is a medical device company based in Galway, Ireland. It specializes in developing catheter-based aspiration technology designed to treat acute ischemic stroke efficiently and effectively.

Ria Health is an online platform that provides telehealth services aimed at helping individuals modify their relationship with alcohol. It offers personalized treatment plans that include medication-assisted options and behavioral therapies, all facilitated by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability. Ria Health also features a mobile app that provides access to educational materials, support groups, and communication with care teams. This comprehensive approach is designed to assist users in managing alcohol consumption and fostering healthier habits, ultimately addressing the challenges associated with alcohol use disorder.

AdvanCell is a clinical-stage company developing novel radiopharmaceuticals for cancer treatment. It specializes in attaching alpha-emitting isotopes to molecules that deliver cytotoxic radiation directly to tumors, aiming to provide safe and effective therapies for multiple cancer types.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Enara Bio Limited is a biotechnology company based in Oxford, United Kingdom, specializing in the development of vaccines and immunotherapies for cancer treatment and prevention. Founded in 2016 and previously known as ErVaxx Limited, the company focuses on creating targeted cancer immunotherapies by exploring novel antigens derived from endogenous retroviral DNA sequences. Enara Bio's technology platform enables the identification and assessment of tumor specificity and immunogenic potential, facilitating improved strategies for combating various cancers. Through its innovative approach, the company aims to provide effective therapeutic options for a broad patient population.

SpectraWAVE is a medical device company that develops intravascular optical imaging systems to diagnose and treat cardiovascular disease. Its technology integrates imaging and computation to help interventional cardiologists identify vulnerable plaques and guide coronary interventions, improving outcomes for patients with coronary artery disease. Headquartered in Waltham, Massachusetts, the company was founded in 2017.

CSA Medical, Inc., established in 1993 and headquartered in Baltimore, Maryland, specializes in the development and manufacturing of spray cryotherapy medical devices. Its primary product, truFreeze, utilizes cold liquid nitrogen to destroy unwanted tissue across dermatology, gynecology, and general surgery fields while promoting healthy tissue regrowth. CSA Medical also offers the Rapid AV Spray Kit to enhance truFreeze's efficiency. The company operates a research and development facility in Lexington, Massachusetts.

Spineology Inc. is a medical device company specializing in anatomy-conserving technology solutions for spine surgery. Founded in 1996 and headquartered in Saint Paul, Minnesota, the company offers a range of products designed to enhance surgical efficiency and improve patient outcomes. Its product lineup includes pedicular fixation systems like Threshold and Fortress, interbody fusion solutions such as Duo and Rampart, and biologics like the Prime liquid tissue matrix and Armor amniotic wound covering. Additionally, Spineology provides a variety of surgical instruments, including the Capture facet fixation system, VIA spinous process fixation system, and Medius midline retractor system, among others. The company focuses on using minimally invasive techniques to reduce post-operative pain and facilitate quicker recovery for patients suffering from spinal-related issues.

Brixton Biosciences is a clinical-stage life sciences company developing therapies for pain management. The company focuses on non-addictive, locally targeted treatments delivered via a drug-free injectable that produces reversible nerve inhibition, aiming to provide long-lasting relief. Its lead approach seeks to extend pain relief from a single injection to thirty to sixty days, reducing reliance on systemic medications and addressing unmet needs in both chronic and acute pain.

Miach Orthopaedics is a medical device company based in Westborough, Massachusetts, specializing in the development of bio-engineered surgical implants aimed at promoting new tissue growth and aiding in connective tissue repair. Founded in 2016, the company focuses on its innovative Bridge-Enhanced ACL Repair technology, which serves as an alternative to traditional anterior cruciate ligament (ACL) reconstruction. This technology provides surgeons with a method to restore the normal anatomy and function of the knee for patients who have experienced ACL injuries, offering a promising option for recovery and rehabilitation.

Eyebiotech is a vision treatment company that develops products to preserve, repair, and improve eyesight. The firm guards against sight-threatening eye disorders and developed the first anti-vascular endothelial growth factor medication for patients with age-related macular degeneration, allowing those with eye ailments to regain their eyesight.

Sitryx Therapeutics is a biopharmaceutical company based in Oxford, United Kingdom, established in 2018. The company specializes in developing disease-modifying therapeutics that target immuno-oncology and immuno-inflammation by regulating cell metabolism. Through its innovative approach, Sitryx aims to correct and alter immune cell functions to inhibit tumor growth. Co-founded by a team of renowned scientists from both the United States and Europe, Sitryx is committed to advancing the field of immunometabolism. The company has a diverse pipeline of projects at various stages of drug discovery, supported by significant investments from a syndicate of specialist investors.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

Robling Medical is a specialized manufacturer serving the healthcare industry. It offers contract manufacturing services tailored for medical organizations, focusing on product design and development through to assembly process design, manufacturing, packaging, sterilization, and distribution of medical products. The company aims to facilitate clients' engineering needs and ensure regulatory compliance, supporting them in bringing their medical devices to market efficiently.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies for treating inflammatory neurological and retinal diseases. Its therapeutics are based on unique insights into the role of fibrin in driving chronic innate immune activation, addressing high unmet needs in various diseases.

PayMedix began as the healthcare payment platform for Health Payment Systems (HPS) in 2008. HPS, headquartered in Milwaukee, Wisconsin, is a privately held healthcare technology and services organization with an independent network of 96 hospital facilities and 22,600 individual providers. PayMedix has processed more than $5 billion in medical payments for hospital systems and physician practices and can be implemented with any PPO or HMO network.

Alpheus Medical develops a sonodynamic therapy platform for solid tumors, combining a drug with a device activated by ultrasound to deliver targeted treatment for recurrent glioblastoma multiforme and other cancers. The non-invasive outpatient approach aims to avoid imaging and hospital admission while concentrating therapy on malignant tissues.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

Ria Health is an online platform that provides telehealth services aimed at helping individuals modify their relationship with alcohol. It offers personalized treatment plans that include medication-assisted options and behavioral therapies, all facilitated by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability. Ria Health also features a mobile app that provides access to educational materials, support groups, and communication with care teams. This comprehensive approach is designed to assist users in managing alcohol consumption and fostering healthier habits, ultimately addressing the challenges associated with alcohol use disorder.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Eyebiotech is a vision treatment company that develops products to preserve, repair, and improve eyesight. The firm guards against sight-threatening eye disorders and developed the first anti-vascular endothelial growth factor medication for patients with age-related macular degeneration, allowing those with eye ailments to regain their eyesight.

Founded in 2018, Perfuze is a medical device company based in Galway, Ireland. It specializes in developing catheter-based aspiration technology designed to treat acute ischemic stroke efficiently and effectively.

Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.

Alpheus Medical develops a sonodynamic therapy platform for solid tumors, combining a drug with a device activated by ultrasound to deliver targeted treatment for recurrent glioblastoma multiforme and other cancers. The non-invasive outpatient approach aims to avoid imaging and hospital admission while concentrating therapy on malignant tissues.

Zerigo Health develops innovative medical devices that deliver narrowband UVB light therapy for chronic skin conditions such as psoriasis, eczema, and vitiligo. Their flagship product, Clarify Medical, is a connected phototherapy system that enables patients to administer treatments at home under physician prescription, ensuring clinical precision while promoting convenience and empowerment.

Eyebiotech is a vision treatment company that develops products to preserve, repair, and improve eyesight. The firm guards against sight-threatening eye disorders and developed the first anti-vascular endothelial growth factor medication for patients with age-related macular degeneration, allowing those with eye ailments to regain their eyesight.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies for treating inflammatory neurological and retinal diseases. Its therapeutics are based on unique insights into the role of fibrin in driving chronic innate immune activation, addressing high unmet needs in various diseases.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

PayMedix began as the healthcare payment platform for Health Payment Systems (HPS) in 2008. HPS, headquartered in Milwaukee, Wisconsin, is a privately held healthcare technology and services organization with an independent network of 96 hospital facilities and 22,600 individual providers. PayMedix has processed more than $5 billion in medical payments for hospital systems and physician practices and can be implemented with any PPO or HMO network.

Leiters Health is an FDA-registered 503B outsourcing provider specializing in high-quality compounded sterile preparations for ophthalmology and hospital-based services. With nearly a century of experience, the company is dedicated to delivering essential medications to healthcare professionals and their patients. Leiters Health offers a comprehensive portfolio that includes ready-to-administer products such as pre-filled syringes, vials, bags, and injectable compounds, as well as opioid-free surgical pain services and specialized cardioplegic and ophthalmic products. The company's team of experts in sterile pharmaceutical manufacturing and compounding employs robust processes and advanced manufacturing facilities to ensure the highest standards of quality and consistency in their offerings, prioritizing patient safety and trust.

Catamaran Bio, Inc. is a biotechnology company focused on developing allogeneic CAR-NK immune cell therapies for the treatment of solid tumors and other cancers. Founded in 2019 and based in Cambridge, Massachusetts, the company utilizes its Tailwind platform to engineer, expand, and process natural killer (NK) cells into off-the-shelf CAR-NK cell therapy products. By leveraging genetic engineering, Catamaran Bio aims to address significant unmet medical needs in cancer treatment, providing transformative therapies for patients.

AavantiBio, Inc. is a biopharmaceutical company focused on developing gene transfer and gene editing therapies aimed at treating rare genetic diseases. Incorporated in 2019 and based in Gainesville, Florida, the company primarily concentrates on Friedreich’s Ataxia, a rare inherited disorder that leads to significant cardiac and central nervous system dysfunction. AavantiBio is committed to transforming the lives of patients suffering from this condition by advancing innovative therapies that address unmet medical needs in the field of genetic disorders. The company’s efforts are directed toward both treatment development and research, with the goal of providing effective solutions for patients facing the challenges of rare diseases.

Alchemab Therapeutics Ltd is a biotechnology company based in London, United Kingdom, focusing on the discovery and development of novel therapeutics aimed at patients with hard-to-treat diseases. Established in 2019 by Uri Laserson and Jane Osbourn, the company utilizes a transformative approach to identify drug targets and build a pipeline of antibody therapeutics. Alchemab's strategy involves harnessing naturally protective antibodies through an unbiased and function-first methodology that employs complementary processes and technologies. This innovative approach aims to provide treatments for various challenging conditions, including hard-to-treat cancers, neurodegenerative disorders, and infectious diseases.

Evidation Health, Inc. is a California-based company that specializes in developing digital tools and technologies for healthcare data analytics. Founded in 2012, the company connects digital health firms with healthcare providers, payers, and other stakeholders through its advanced technology solutions. Its primary offerings include a data platform that transforms everyday behavior data from various sources, such as sensors and devices, into meaningful health insights, and a technology-enabled service called Studies that facilitates real-world research using this data. Evidation Health aims to enhance the understanding of how daily behaviors impact health and disease, ultimately empowering individuals to engage in better health outcomes. The company's commitment to user privacy and control over health data has garnered trust from millions of individuals, enabling them to participate in innovative health programs and research.

Amwell is a leading global telehealth platform connecting providers, insurers, patients, and innovators to deliver accessible, affordable, high-quality care. Established in 2006, Amwell offers a comprehensive platform supporting urgent to chronic care management, serving over 240 health systems, 55 health plans, and reaching over 150 million lives worldwide.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Caraway Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing innovative treatments for neurodegenerative diseases by modulating mitophagy and autophagy. The company aims to address the degradation of toxic cellular components, which is a key factor in various neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis. By leveraging an understanding of critical neural pathways, Caraway Therapeutics seeks to discover and develop novel small molecules that can restore cellular balance and improve lysosomal function. Founded in 2018 and initially known as Rheostat Therapeutics, Inc., the company rebranded in 2019 to reflect its commitment to finding effective therapies for patients affected by these debilitating diseases.

Zarodex Therapeutics is a biotechnology company that treats dementia and Alzheimer's diseases.

CytoMed Therapeutics specializes in developing off-the-shelf immunotherapeutics using gamma delta T cells and natural killer cells to treat various tumors. It also generates induced pluripotent stem cells for cellular medicines.

EBT Medical, Inc. is a clinical-stage company based in Boston, Massachusetts, with an additional office in Toronto, Canada. Founded in 2014, the company specializes in developing innovative, non-invasive neuromodulation therapies aimed at treating pelvic health disorders, particularly focusing on patients with overactive bladder. EBT Medical's technology is centered on the Saphenous nerve and is designed to provide discreet treatment options that enable patients to restore pelvic health function without the side effects typically associated with conventional therapies. The company emerged from scientific discoveries made at the University of Toronto and has benefited from a startup incubation program that has fostered numerous successful ventures in the past decade.

Enara Bio Limited is a biotechnology company based in Oxford, United Kingdom, specializing in the development of vaccines and immunotherapies for cancer treatment and prevention. Founded in 2016 and previously known as ErVaxx Limited, the company focuses on creating targeted cancer immunotherapies by exploring novel antigens derived from endogenous retroviral DNA sequences. Enara Bio's technology platform enables the identification and assessment of tumor specificity and immunogenic potential, facilitating improved strategies for combating various cancers. Through its innovative approach, the company aims to provide effective therapeutic options for a broad patient population.

Healthify, Inc. is a New York-based company that specializes in community referral and social determinants management software for healthcare organizations, including health plans, hospitals, and provider networks. Founded in 2013, Healthify's platform aims to enhance the coordination of social services by providing tools such as Healthify Search, which identifies resources for social or behavioral health needs; Healthify Track, designed to understand and report on population needs and referrals; Healthify Coordinate, which facilitates collaboration among key partners; and Healthify Measure, which assesses outcomes and fosters accountability. The company emphasizes building accountable networks of community-based organizations and aims to demonstrate the return on investment for social service interventions, ensuring that families access necessary services to improve their health and well-being. Healthify collaborates with partners across all fifty states to support social determinants of health initiatives effectively.

Zerigo Health develops innovative medical devices that deliver narrowband UVB light therapy for chronic skin conditions such as psoriasis, eczema, and vitiligo. Their flagship product, Clarify Medical, is a connected phototherapy system that enables patients to administer treatments at home under physician prescription, ensuring clinical precision while promoting convenience and empowerment.

Founded in 2013, Bardy Diagnostics specializes in developing advanced cardiac monitoring devices. Its flagship product is the Carnation Ambulatory Monitor (CAM), a discreet and comfortable patch monitor designed to capture clear P-wave signals for accurate arrhythmia detection. The company also offers BDxCONNECT, a patient management system that aids clinical decision-making by providing easy access to CAM reports.

CSA Medical, Inc., established in 1993 and headquartered in Baltimore, Maryland, specializes in the development and manufacturing of spray cryotherapy medical devices. Its primary product, truFreeze, utilizes cold liquid nitrogen to destroy unwanted tissue across dermatology, gynecology, and general surgery fields while promoting healthy tissue regrowth. CSA Medical also offers the Rapid AV Spray Kit to enhance truFreeze's efficiency. The company operates a research and development facility in Lexington, Massachusetts.

myOrthos is a comprehensive orthodontic platform dedicated to enhancing patient care and fostering a community of excellence in orthodontics. The company offers a range of support services to orthodontists and their teams, including office management, billing and collections, capital management, succession planning, marketing, staff recruitment, and training. These services help orthodontic practices navigate various challenges, particularly those related to practice transitions.

Caraway Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing innovative treatments for neurodegenerative diseases by modulating mitophagy and autophagy. The company aims to address the degradation of toxic cellular components, which is a key factor in various neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis. By leveraging an understanding of critical neural pathways, Caraway Therapeutics seeks to discover and develop novel small molecules that can restore cellular balance and improve lysosomal function. Founded in 2018 and initially known as Rheostat Therapeutics, Inc., the company rebranded in 2019 to reflect its commitment to finding effective therapies for patients affected by these debilitating diseases.

Urgent Team Holdings, Inc. operates urgent care centers, offering immediate and primary healthcare services. Their centers serve suburban neighborhoods, rural towns, and underserved communities, providing a wide range of services including treatment for injuries, illnesses, and preventive screenings. They also offer occupational health services and wellness care, ensuring affordable and convenient walk-in medical services for patients.

Sitryx Therapeutics is a biopharmaceutical company based in Oxford, United Kingdom, established in 2018. The company specializes in developing disease-modifying therapeutics that target immuno-oncology and immuno-inflammation by regulating cell metabolism. Through its innovative approach, Sitryx aims to correct and alter immune cell functions to inhibit tumor growth. Co-founded by a team of renowned scientists from both the United States and Europe, Sitryx is committed to advancing the field of immunometabolism. The company has a diverse pipeline of projects at various stages of drug discovery, supported by significant investments from a syndicate of specialist investors.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Endotronix develops and manufactures implantable wireless pulmonary artery pressure sensors for early detection of worsening heart failure. The company's platform includes a cloud-based disease management data system, enabling remote patient monitoring.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company that develops a novel class of medicines called Bicycles, synthetic short peptides constrained to form two loops that stabilize their structure. Its lead program BT1718 is a Bicycle Toxin Conjugate for oncology, with Phase I/IIa trials in tumors expressing Membrane Type 1 matrix metalloprotease. The company is also advancing BT5528, a BTC targeting EphA2, and BT8009 in preclinical development for Nectin-4, along with preclinical CD137 and THR-149, a plasma kallikrein inhibitor for diabetic macular edema. Beyond its internal programs, Bicycle Therapeutics collaborates with Cancer Research Technology, Cancer Research UK, AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund, and has a discovery collaboration with Genentech for immuno-oncology targets. The company was founded in 2009 and is headquartered in Cambridge, United Kingdom.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

Evidation Health, Inc. is a California-based company that specializes in developing digital tools and technologies for healthcare data analytics. Founded in 2012, the company connects digital health firms with healthcare providers, payers, and other stakeholders through its advanced technology solutions. Its primary offerings include a data platform that transforms everyday behavior data from various sources, such as sensors and devices, into meaningful health insights, and a technology-enabled service called Studies that facilitates real-world research using this data. Evidation Health aims to enhance the understanding of how daily behaviors impact health and disease, ultimately empowering individuals to engage in better health outcomes. The company's commitment to user privacy and control over health data has garnered trust from millions of individuals, enabling them to participate in innovative health programs and research.

Sutro Biopharma is a clinical-stage biopharmaceutical company focused on developing next-generation protein therapeutics for cancer and autoimmune disorders using its proprietary XpressCF platform. Its pipeline includes STRO-001 for multiple myeloma and non-Hodgkin lymphoma, and STRO-002 for ovarian and endometrial cancers.

Centauri Health Solutions is a technology-focused company that provides cloud-based software and data management services tailored for the healthcare sector. The company's platform assists hospitals with various functions, including medical record retrieval and coding, quality program management, eligibility and enrollment, and healthcare data analytics. By leveraging sophisticated analytics and data-driven services, Centauri aims to enhance the health outcomes of patients while helping clients optimize government-sponsored healthcare reimbursement. Their commitment to compassionate outreach and effective data management supports healthcare organizations in improving operational efficiencies and delivering better care to their members.

LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease and other triplet repeat diseases.

Pionyr Immunotherapeutics Inc. is a biotechnology company focused on developing innovative cancer immunotherapies that specifically target the tumor microenvironment to enhance the body's antitumor immunity. Founded in 2015 and based in San Francisco, California, Pionyr leverages advanced target discovery and antibody generation platform technologies to create next-generation immuno-oncology therapeutics. The company's proprietary approach, known as Myeloid Tuning™, aims to improve the immune system’s anti-tumor response by precisely altering the cellular composition within the tumor microenvironment. This strategy is designed to enable patients to better combat cancer, particularly when used in conjunction with checkpoint inhibitors.

Misonix is a leading medical device company specializing in ultrasonic surgical technology. The company designs, manufactures, and markets innovative devices that enhance clinical outcomes in various surgical fields, including neurosurgery, orthopedic surgery, plastic surgery, and wound care. Misonix's product portfolio features advanced ultrasonic platforms such as aspirators for soft and hard tissue removal, instruments for laparoscopic procedures, and devices for wound cleansing and debridement. Additionally, its offerings include tools for precision bone cutting and sculpting, as well as liposuction instruments aimed at improving body aesthetics. Notable products include BoneScalpel, NeXus, Sequel, SonaStar, SonicOne, Theragenesis, TheraSkin, and Therion. Misonix serves a global market, with a presence in regions such as the United States and the United Kingdom, contributing to the overall value of the healthcare system.

Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

Founded in 2013, Bardy Diagnostics specializes in developing advanced cardiac monitoring devices. Its flagship product is the Carnation Ambulatory Monitor (CAM), a discreet and comfortable patch monitor designed to capture clear P-wave signals for accurate arrhythmia detection. The company also offers BDxCONNECT, a patient management system that aids clinical decision-making by providing easy access to CAM reports.

Pionyr Immunotherapeutics Inc. is a biotechnology company focused on developing innovative cancer immunotherapies that specifically target the tumor microenvironment to enhance the body's antitumor immunity. Founded in 2015 and based in San Francisco, California, Pionyr leverages advanced target discovery and antibody generation platform technologies to create next-generation immuno-oncology therapeutics. The company's proprietary approach, known as Myeloid Tuning™, aims to improve the immune system’s anti-tumor response by precisely altering the cellular composition within the tumor microenvironment. This strategy is designed to enable patients to better combat cancer, particularly when used in conjunction with checkpoint inhibitors.

NKT Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in developing therapeutics based on natural killer T (NKT) cells. Established in 2008, the company focuses on creating a pipeline of first-in-class NKT-based treatments targeting a range of conditions, including sickle cell disease, autoimmune and inflammatory diseases, cancer, asthma, and dermatitis. NKT Therapeutics utilizes a unique biotechnology platform that offers humanized monoclonal antibodies to selectively deplete iNKT cells, which are implicated in organ damage in preclinical models of sickle cell disease. By leveraging its expertise in the intersection of innate and adaptive immunity, NKT Therapeutics aims to provide innovative solutions for complex health challenges.

CardioKinetix develops transcatheter implants for treating heart failure. Its flagship product is Parachute, a ventricular partitioning device designed to improve overall cardiac function in patients who have experienced a heart attack. The company serves customers primarily in the United States and Europe.

CSA Medical, Inc., established in 1993 and headquartered in Baltimore, Maryland, specializes in the development and manufacturing of spray cryotherapy medical devices. Its primary product, truFreeze, utilizes cold liquid nitrogen to destroy unwanted tissue across dermatology, gynecology, and general surgery fields while promoting healthy tissue regrowth. CSA Medical also offers the Rapid AV Spray Kit to enhance truFreeze's efficiency. The company operates a research and development facility in Lexington, Massachusetts.

SUN Behavioral Health, Inc. is a provider of behavioral health services, operating freestanding hospitals that cater to a diverse population, including children, youth, adults, seniors, women, and military personnel. Founded in 2013 and headquartered in Red Bank, New Jersey, the company offers a comprehensive range of services such as inpatient psychiatric care, substance abuse treatment, partial hospitalization programs, intensive outpatient programs, 24-hour assessments, and crisis stabilization. SUN Behavioral Health works collaboratively with medical and surgical hospitals, healthcare providers, local schools, and community organizations to ensure a seamless continuum of care, focusing on personalized treatment to address significant unmet behavioral health needs.

Cibiem Inc. is a medical device manufacturer specializing in Carotid Body Modulation (CBM), which targets sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes, and renal failure. Founded in 2010 and based in Los Altos, California, with an additional office in Teaneck, New Jersey, Cibiem utilizes a proprietary, minimally invasive, catheter-based approach to deliver its treatments. The company was co-founded by Mark Gelfand and Howard R. Levin, M.D., who bring a wealth of experience in medical innovation and entrepreneurship. Cibiem aims to enhance the efficacy of medical interventions for serious health conditions, thereby improving patient outcomes in the treatment of these critical disorders.

ValenTx, Inc. is a medical device company based in Maple Grove, Minnesota, that specializes in developing innovative therapy solutions for patients suffering from obesity and obesity-related metabolic disorders. Founded in 2002, ValenTx focuses on minimally-invasive treatment methods, including an endoluminal bypass therapy that replicates the anatomical changes of the traditional Roux-en-Y gastric bypass procedure. This technology features an adjustable, removable, and replaceable device designed to address conditions such as type-2 diabetes and hypertension, aiming to improve patient outcomes in the management of these chronic health issues.

Maestro Health is an employee benefits company based in Chicago, Illinois, founded in 2013. It specializes in providing integrated solutions for brokers, small employers, and Fortune 1000 organizations, offering a comprehensive "one-stop shopping" experience for employee health and benefits management. The company's services include private exchange solutions, benefits administration, enrollment, self-insurance, and healthcare savings account management, all accessible through its integrated mobile and web platform, maestroEDGE. Maestro Health operates its own proprietary private exchange and serves as a medical third-party administrator (TPA), which facilitates the streamlined integration of care management, ultimately helping employers reduce costs. The company was previously known as Maestro Healthcare Technology, Inc. and rebranded to Maestro Health in April 2014. As of 2018, Maestro Health operates as a subsidiary of AXA US Holdings Inc.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company that develops a novel class of medicines called Bicycles, synthetic short peptides constrained to form two loops that stabilize their structure. Its lead program BT1718 is a Bicycle Toxin Conjugate for oncology, with Phase I/IIa trials in tumors expressing Membrane Type 1 matrix metalloprotease. The company is also advancing BT5528, a BTC targeting EphA2, and BT8009 in preclinical development for Nectin-4, along with preclinical CD137 and THR-149, a plasma kallikrein inhibitor for diabetic macular edema. Beyond its internal programs, Bicycle Therapeutics collaborates with Cancer Research Technology, Cancer Research UK, AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund, and has a discovery collaboration with Genentech for immuno-oncology targets. The company was founded in 2009 and is headquartered in Cambridge, United Kingdom.

CardioFocus develops endoscopic ablation systems for atrial fibrillation, including the HeartLight Endoscopic Ablation System with direct visualization and energy-delivery capabilities for pulmonary vein isolation, as well as the HeartLight Excalibur Balloon and HeartLight X3 System for stable tissue contact and controlled lesion creation across varying pulmonary vein anatomies. The company integrates a balloon catheter, endoscope, deflectable sheath, and console to enable electrophysiologists to tailor ablations to patient needs. Founded in 1990 and based in Marlborough, Massachusetts, CardioFocus aims to advance treatment of cardiac arrhythmias through visualization-guided devices.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at improving near vision. Founded in 2001, the company develops and markets innovative solutions for presbyopia, including the KAMRA inlay, which helps patients restore their near vision without compromising distance vision. Additionally, AcuFocus offers the IC-8 IOL, a small aperture lens designed for cataract patients, providing a broad range of vision from near to far distances. The company also produces the AcuTarget HD, a diagnostic and surgical planning instrument that assists in the optimal treatment selection for various eye conditions such as LASIK, cataracts, and dry eye. AcuFocus distributes its products through partners across the Americas, Asia-Pacific, Europe, and the Middle East, serving both physicians and patients in the vision care market.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

Kesios Therapeutics, established in 2012, is a UK-based biopharmaceutical company focused on developing small molecule drugs for haematological malignancies, primarily multiple myeloma. The company's pipeline targets key pathways like NF-κB and GADD45β/MKK7, aiming to address unmet medical needs in oncology.

Aligned TeleHealth, established in 2001 and headquartered in Woodland Hills, California, specializes in providing comprehensive behavioral health services to various healthcare facilities. The company offers on-site staffing solutions for hospitals, long-term care facilities, and outpatient clinics, along with hospital-based care, psychiatric outpatient services, telehealth consultations, and long-term care programs. Its SaaS platform facilitates full end-to-end telemedicine services, enabling clients to deliver enhanced quality and efficient patient care across acute-care hospitals, emergency rooms, skilled nursing facilities, and correctional institutions.

SUN Behavioral Health, Inc. is a provider of behavioral health services, operating freestanding hospitals that cater to a diverse population, including children, youth, adults, seniors, women, and military personnel. Founded in 2013 and headquartered in Red Bank, New Jersey, the company offers a comprehensive range of services such as inpatient psychiatric care, substance abuse treatment, partial hospitalization programs, intensive outpatient programs, 24-hour assessments, and crisis stabilization. SUN Behavioral Health works collaboratively with medical and surgical hospitals, healthcare providers, local schools, and community organizations to ensure a seamless continuum of care, focusing on personalized treatment to address significant unmet behavioral health needs.

Founded in 2005, Halscion specializes in developing biocompatible hydrogel scaffolds designed to improve wound healing and reduce scarring. These single-use devices are applied during surgeries at the dermal-subdermal interface of wounds by injection, allowing the patient's own cells to organize and propagate into the wound.

Direct Flow Medical is a medical device company specializing in the development of innovative transcatheter aortic valve replacement systems aimed at treating heart valve diseases. The company's primary focus is on creating a percutaneous aortic tissue valve prosthesis, which offers patients suffering from cardiac valve insufficiency a safe and effective treatment option. With approximately 1.2 million individuals over the age of 65 affected by calcified aortic valves, and only about 150,000 receiving surgical intervention annually, Direct Flow Medical addresses a significant gap in patient care. Their technology allows heart surgeons to conduct repeated assessments of hemodynamic performance prior to final implantation, thereby enhancing patient outcomes and minimizing complications associated with invasive surgeries.

Endotronix develops and manufactures implantable wireless pulmonary artery pressure sensors for early detection of worsening heart failure. The company's platform includes a cloud-based disease management data system, enabling remote patient monitoring.

CardioFocus develops endoscopic ablation systems for atrial fibrillation, including the HeartLight Endoscopic Ablation System with direct visualization and energy-delivery capabilities for pulmonary vein isolation, as well as the HeartLight Excalibur Balloon and HeartLight X3 System for stable tissue contact and controlled lesion creation across varying pulmonary vein anatomies. The company integrates a balloon catheter, endoscope, deflectable sheath, and console to enable electrophysiologists to tailor ablations to patient needs. Founded in 1990 and based in Marlborough, Massachusetts, CardioFocus aims to advance treatment of cardiac arrhythmias through visualization-guided devices.

AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at improving near vision. Founded in 2001, the company develops and markets innovative solutions for presbyopia, including the KAMRA inlay, which helps patients restore their near vision without compromising distance vision. Additionally, AcuFocus offers the IC-8 IOL, a small aperture lens designed for cataract patients, providing a broad range of vision from near to far distances. The company also produces the AcuTarget HD, a diagnostic and surgical planning instrument that assists in the optimal treatment selection for various eye conditions such as LASIK, cataracts, and dry eye. AcuFocus distributes its products through partners across the Americas, Asia-Pacific, Europe, and the Middle East, serving both physicians and patients in the vision care market.

Karus Therapeutics Limited is a biopharmaceutical company based in Oxfordshire, United Kingdom, that specializes in the development of small molecule drugs aimed at treating cancer and immune/inflammatory disorders. Founded in 2005, the company focuses on designing innovative, molecular-targeted therapies. Its portfolio includes orally-active drugs such as KA2237, a dual-selective inhibitor of PI3K isoforms effective against hematological and solid tumors, and KA2507, which targets HDAC6 for tumors expressing PD-L1. By combining targeted therapy with immunotherapeutic activity, Karus Therapeutics aims to provide effective treatment options for a diverse range of cancers.

Jet Health Solutions is a technology company specializing in healthcare solutions. Its primary product, JET Insure, is a cloud-based platform enabling healthcare payers to automate insurance processes, offering individual/family plans, group plans, stop-loss/self-funded options, and specialty products.

VHsquared Ltd. is a biotechnology company focused on developing oral biologics for immuno-inflammatory conditions affecting the gastrointestinal tract. Founded in 2010 and based in Cambridge, United Kingdom, VHsquared utilizes its proprietary Vorabody platform to create engineered domain antibodies that are resistant to degradation in the gut, allowing for effective oral administration. This innovative approach addresses the limitations of conventional antibodies, which are typically broken down in the gastrointestinal system. The company aims to produce a range of functional food products that target gastrointestinal infections and immune-mediated diseases, leveraging advancements in mucosal immunology and microbiota analysis. By developing therapies that are stable, specific, and locally active, VHsquared seeks to provide safer, more effective treatment options for patients with inflammatory bowel diseases and related conditions.

Soffio Medical, Inc. is a Boston-based company focused on developing innovative medical devices for respiratory diseases. The firm specializes in implantable technologies that aim to address chronic obstructive pulmonary disease (COPD) and similar conditions. Its devices are designed to implement an airway bypass concept, allowing for the venting of trapped air from areas distal to high-resistance airways. This approach helps reduce residual lung volume and alleviates symptoms associated with respiratory diseases, ultimately enhancing the quality of life for patients.

AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at improving near vision. Founded in 2001, the company develops and markets innovative solutions for presbyopia, including the KAMRA inlay, which helps patients restore their near vision without compromising distance vision. Additionally, AcuFocus offers the IC-8 IOL, a small aperture lens designed for cataract patients, providing a broad range of vision from near to far distances. The company also produces the AcuTarget HD, a diagnostic and surgical planning instrument that assists in the optimal treatment selection for various eye conditions such as LASIK, cataracts, and dry eye. AcuFocus distributes its products through partners across the Americas, Asia-Pacific, Europe, and the Middle East, serving both physicians and patients in the vision care market.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company that develops a novel class of medicines called Bicycles, synthetic short peptides constrained to form two loops that stabilize their structure. Its lead program BT1718 is a Bicycle Toxin Conjugate for oncology, with Phase I/IIa trials in tumors expressing Membrane Type 1 matrix metalloprotease. The company is also advancing BT5528, a BTC targeting EphA2, and BT8009 in preclinical development for Nectin-4, along with preclinical CD137 and THR-149, a plasma kallikrein inhibitor for diabetic macular edema. Beyond its internal programs, Bicycle Therapeutics collaborates with Cancer Research Technology, Cancer Research UK, AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund, and has a discovery collaboration with Genentech for immuno-oncology targets. The company was founded in 2009 and is headquartered in Cambridge, United Kingdom.

Cibiem Inc. is a medical device manufacturer specializing in Carotid Body Modulation (CBM), which targets sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes, and renal failure. Founded in 2010 and based in Los Altos, California, with an additional office in Teaneck, New Jersey, Cibiem utilizes a proprietary, minimally invasive, catheter-based approach to deliver its treatments. The company was co-founded by Mark Gelfand and Howard R. Levin, M.D., who bring a wealth of experience in medical innovation and entrepreneurship. Cibiem aims to enhance the efficacy of medical interventions for serious health conditions, thereby improving patient outcomes in the treatment of these critical disorders.

Maestro Health is an employee benefits company based in Chicago, Illinois, founded in 2013. It specializes in providing integrated solutions for brokers, small employers, and Fortune 1000 organizations, offering a comprehensive "one-stop shopping" experience for employee health and benefits management. The company's services include private exchange solutions, benefits administration, enrollment, self-insurance, and healthcare savings account management, all accessible through its integrated mobile and web platform, maestroEDGE. Maestro Health operates its own proprietary private exchange and serves as a medical third-party administrator (TPA), which facilitates the streamlined integration of care management, ultimately helping employers reduce costs. The company was previously known as Maestro Healthcare Technology, Inc. and rebranded to Maestro Health in April 2014. As of 2018, Maestro Health operates as a subsidiary of AXA US Holdings Inc.

Thesan Pharmaceuticals, Inc. is a biopharmaceutical company based in Carlsbad, California, that specializes in the development of novel therapeutics for skin disorders. Founded in 2011, the company is dedicated to creating innovative treatments for dermatological conditions, particularly atopic dermatitis and acne. Unlike many competitors who primarily focus on reformulating existing medications with limited advancements, Thesan aims to discover and develop new chemical entities that promise substantially improved therapeutic options for patients. This commitment to innovation addresses the growing need for effective solutions in a field that has seen relatively little progress in recent years.

AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at improving near vision. Founded in 2001, the company develops and markets innovative solutions for presbyopia, including the KAMRA inlay, which helps patients restore their near vision without compromising distance vision. Additionally, AcuFocus offers the IC-8 IOL, a small aperture lens designed for cataract patients, providing a broad range of vision from near to far distances. The company also produces the AcuTarget HD, a diagnostic and surgical planning instrument that assists in the optimal treatment selection for various eye conditions such as LASIK, cataracts, and dry eye. AcuFocus distributes its products through partners across the Americas, Asia-Pacific, Europe, and the Middle East, serving both physicians and patients in the vision care market.

Atopix Therapeutics Limited is a clinical-stage biopharmaceutical company based in Oxford, United Kingdom, focused on developing innovative anti-inflammatory medicines for the treatment of asthma, chronic allergic conditions, and other atopic diseases. Founded in 2012, the company specializes in a novel class of oral anti-allergic medications known as CRTH2 antagonists. Its lead candidate is currently undergoing a Phase 2 clinical trial aimed at addressing moderate to severe atopic dermatitis, with studies being conducted at several prominent dermatology centers across Europe. Atopix Therapeutics operates as a subsidiary of Chiesi Farmaceutici S.p.A.

Doctors of Physical Therapy, founded in 2004 and located in Elgin, Illinois, specializes in providing a comprehensive range of physical therapy services. The company operates clinics and also offers on-site therapy for large employers. Its services encompass injury screening, manual therapies, surgical therapy, fall prevention, vestibular therapy, concussion therapy, sports rehabilitation, and post-operative rehabilitation. In addition, the company addresses chronic pain, pelvic floor issues, pediatric therapy, hand therapy, and functional capacity evaluations. With a focus on personalized treatment plans, Doctors of Physical Therapy aims to meet the diverse needs of its patients, whether through in-clinic, in-home, or online care.

Kesios Therapeutics, established in 2012, is a UK-based biopharmaceutical company focused on developing small molecule drugs for haematological malignancies, primarily multiple myeloma. The company's pipeline targets key pathways like NF-κB and GADD45β/MKK7, aiming to address unmet medical needs in oncology.

ReShape Lifesciences is a medical device company focused on technologies to treat obesity and metabolic diseases. The company develops and commercializes products designed to provide less invasive options for weight loss, including the Lap-Band System, an adjustable gastric banding device for long-term obesity management. It also has the ReShape Vest system, an investigational laparoscopically implanted device that wraps around the stomach and is designed to support weight loss without permanent changes to the GI tract; the Vest is primarily marketed outside the United States. The company traces its origins to EnteroMedics and adopted the ReShape Lifesciences name in 2017. It is headquartered in San Clemente, California, and operates in multiple international markets.

Avitide, Inc. specializes in the discovery, manufacture, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. Founded in 2012 and based in Lebanon, New Hampshire, the company focuses on developing customized affinity purification products that improve the efficiency and effectiveness of bioprocessing. Avitide's technology enhances the purification of therapeutic proteins, including enzymes, antibodies, gene therapies, and vaccines, by employing rapid development of chromatography resins through chemical synthesis. This advanced platform enables clients to accelerate bioprocess development timelines, mitigate program risks, and achieve predictable commercial scalability while lowering manufacturing costs in both batch and continuous operations.